- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03144011
Acute Kidney Injury in Children After Cardiopulmonary Bypass
Early Diagnosis of Acute Kidney Injury in Children With Congenital Heart Disease After Cardiopulmonary Bypass
Acute kidney injury (AKI) is a common complication in patients with congenital heart defects after cardiopulmonary bypass. The death rate from AKI in critically ill children remains high and reaches 60%.
The basic criteria for diagnosing and assessing the severity of kidney injury until recently were the level of serum creatinine and the amount of urine released. However, it should be noted that the level of serum creatinine, traditionally used to assess renal function, does not significantly increase until a decrease of more than 50% of the glomerular filtration rate, in addition, its level depends also on some extrarenal causes. Artificial blood circulation and hemodilution leads to the preservation of the level of creatinine at sufficiently low levels up to 1-3 days postoperative period. The level of diuresis as well as the level of creatinine is a nonspecific criterion after cardiac surgery and depends on several factors.
Currently, in the field of acute renal injury studies, progress has been made in the emergence of new biomarkers such as the tissue inhibitor metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding globulin-7 (IGFBP7), which are early markers of acute renal damage. In a study in adult patients, it was shown that the levels of TIMP-2 and IGFBP7 increased In the first 24-48 before the diagnosis of IR-associated renal damage.
Among pediatric patients with congenital heart defects, such studies are single and only present for the age group 3 and older, which also demonstrated the high specificity and prognostic significance of these biomarkers in the early diagnosis of acute renal damage.
It should also be noted that, in spite of the high specificity of the markers described, it is also necessary to note their considerable cost.
Thus, taking into account the above, it is planned to compare and identify the relationship of these indicators with such parameter as the index of renal vascular resistance, the increase of which in the pre- and postoperative period may serve as a sign of the beginning acute renal injury.
Study Overview
Status
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Novosibirsk Region
-
Novosibirsk, Novosibirsk Region, Russian Federation, 630055
- Siberian Biomedical Research Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Age from 1 month to 1 year Presence of congenital heart disease Radical correction of the defect in conditions of cardiopulmonary bypass
Exclusion Criteria:
Inconsistency with age criteria Cardiotonic support before surgery Acute renal, acute liver failure before surgery
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
acute renal injury on the scale pRIFLE
Time Frame: 48 hours
|
diagnosis of acute kidney injury after cardiac surgery
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TIMP-2
Time Frame: 6 hours
|
elevation of TIMP-2 after cardiac surgery
|
6 hours
|
|
renal resistant index with doppler ultrasound
Time Frame: before, 6 hour, 24 hour
|
with doppler ultrasound
|
before, 6 hour, 24 hour
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20.03 №194
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiopulmonary Bypass
-
Baxter Healthcare CorporationCompletedCardiopulmonary Bypass | Sternotomy | Cardiac Surgery Requiring Cardiopulmonary Bypass and Median SternotomyUnited States
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedCardiopulmonary Bypass | Coronary Artery Bypass GraftingChina
-
University of Texas Southwestern Medical CenterChildren's Medical Center DallasWithdrawnCardiopulmonary BypassUnited States
-
University Hospital, GhentCompletedCardiopulmonary Bypass
-
Aristotle University Of ThessalonikiCompletedHeparin and Protamine Titration in Cardiac Surgery Under Minimal Invasive Extracorporeal CirculationCardiopulmonary BypassGreece
-
University Medical Centre LjubljanaSlovenian Research AgencyCompleted
-
Ulf BorgMedtronic - MITGCompletedCardiopulmonary BypassChina
-
Emory UniversityChildren's Research Oversight Committee FundsCompletedCardiopulmonary BypassUnited States
-
University of Texas Southwestern Medical CenterChildren's Medical Center DallasWithdrawn
-
University of EdinburghNHS LothianCompleted